Modeling chromosome 7 loss in Myelodysplasia-iPSCs

骨髓增生异常-iPSC 中 7 号染色体缺失的建模

基本信息

项目摘要

DESCRIPTION (provided by applicant): Myelodysplastic syndromes (MDS) are clonal hematologic disorders characterized by ineffective hematopoiesis and a propensity for progression to bone marrow (BM) failure or acute leukemia. Despite their relatively high incidence, very little is known about their pathogenesis and their treatment remains mainly palliative. This is largely due to the unavailability of good animal models and the challenges of the ex vivo culture of primary MDS cells. Loss of the entire or part of chromosome 7 [del(7/7q)] is a recurrent cytogenetic abnormality in MDS, associated with unfavorable prognosis, strongly suggesting that one or more critical genes - that so far remain elusive - reside in chromosome 7q. With recent breakthroughs in human pluripotent stem cell (hPSC) research - direct reprogramming and new genetic engineering technologies - reverse genetics in an isogenic setting by precise disruption of genomic elements into their cognate genomic and cellular context - hitherto unthinkable for the human genome - are now a realistic prospect. Our goal is to harness cutting-edge reprogramming and genetic engineering technologies that we and others have developed to establish a novel hPSC-based model to study the cellular, molecular and genetic pathogenesis of myelodysplasia. In preliminary studies, we have derived MDS-iPSC lines with chromosome 7q deletions from patient BM cells and found that they recapitulate potential disease- associated phenotypes: impaired cell proliferation and hematopoietic differentiation. In the proposed study we plan to derive additional del(7q)- as well as isogenic karyotypically normal iPSCs, through reprogramming and chromosome engineering, and characterize their phenotype in the undifferentiated state and following hematopoietic differentiation. To identify genes with a role in MDS pathogenesis, we will perform a screen of candidate genes residing in chromosome 7q for rescue of proliferation in our del(7q)- hPSCs. These studies, using powerful new technologies, will provide a novel valuable resource for the study of myelodysplasia, generate insights into the cellular processes and molecular pathways affected and potentially identify critical genes in the pathogenesis of MDS, bone marrow failure and preleukemia, in general. !
描述(由申请人提供):骨髓增生异常综合征(MDS)是一种克隆性血液学疾病,其特征是无效造血和进展为骨髓(BM)衰竭或急性白血病的倾向。尽管其发病率相对较高,但对其发病机制知之甚少,其治疗主要是姑息性的。这在很大程度上是由于良好的动物模型的不可用性和原代MDS细胞的离体培养的挑战。7号染色体[del(7/7 q)]的全部或部分缺失是MDS中的复发性细胞遗传学异常,与不利的预后相关,强烈表明一个或多个关键基因-迄今为止仍然难以捉摸-存在于染色体7 q中。随着人类多能干细胞(hPSC)研究的最新突破-直接重编程和新的基因工程技术-通过精确破坏基因组元件进入其同源基因组和细胞背景的等基因环境中的反向遗传学-迄今为止对于人类基因组是不可想象的-现在是一个现实的前景。我们的目标是利用我们和其他人开发的尖端重编程和基因工程技术,建立一种新的基于hPSC的模型,以研究骨髓增生异常的细胞,分子和遗传发病机制。在初步研究中,我们已经从患者BM细胞中衍生出具有染色体7 q缺失的MDS-iPSC系,并且发现它们概括了潜在的疾病相关表型:受损的细胞增殖和造血分化。在拟议的研究中,我们计划通过重编程和染色体工程来获得额外的del(7 q)-以及同基因核型正常的iPSC,并表征其在未分化状态和造血分化后的表型。为了鉴定在MDS发病机制中起作用的基因,我们将进行位于染色体7 q中的候选基因的筛选以拯救我们的del(7 q)-hPSC中的增殖。这些研究,使用强大的新技术,将提供一个新的有价值的资源,骨髓增生异常的研究,产生的细胞过程和分子途径的影响,并可能确定关键基因的发病机制MDS,骨髓衰竭和白血病前期,一般的见解。!

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Eirini Papapetrou其他文献

Eirini Papapetrou的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Eirini Papapetrou', 18)}}的其他基金

Mechanisms and targeting of aberrant Gas activation in myeloid neoplasms
骨髓肿瘤中异常气体​​激活的机制和靶向
  • 批准号:
    10659809
  • 财政年份:
    2023
  • 资助金额:
    $ 42.38万
  • 项目类别:
Impact of mutational order on molecular mechanisms of oncogenesis
突变顺序对肿瘤发生分子机制的影响
  • 批准号:
    10375146
  • 财政年份:
    2022
  • 资助金额:
    $ 42.38万
  • 项目类别:
Mechanisms and therapeutic implications of human clonal hematopoiesis (CH) mutations
人类克隆造血(CH)突变的机制和治疗意义
  • 批准号:
    10643995
  • 财政年份:
    2022
  • 资助金额:
    $ 42.38万
  • 项目类别:
Impact of mutational order on molecular mechanisms of oncogenesis
突变顺序对肿瘤发生分子机制的影响
  • 批准号:
    10620122
  • 财政年份:
    2022
  • 资助金额:
    $ 42.38万
  • 项目类别:
Mechanisms and therapeutic implications of human clonal hematopoiesis (CH) mutations
人类克隆造血(CH)突变的机制和治疗意义
  • 批准号:
    10450238
  • 财政年份:
    2022
  • 资助金额:
    $ 42.38万
  • 项目类别:
Dissecting splicing factor mutations in iPSCs
剖析 iPSC 中的剪接因子突变
  • 批准号:
    9893894
  • 财政年份:
    2017
  • 资助金额:
    $ 42.38万
  • 项目类别:
Dissecting splicing factor mutations in iPSCs
剖析 iPSC 中的剪接因子突变
  • 批准号:
    9317606
  • 财政年份:
    2017
  • 资助金额:
    $ 42.38万
  • 项目类别:
Modeling chromosome 7 loss in Myelodysplasia-iPSCs
骨髓增生异常-iPSC 中 7 号染色体缺失的建模
  • 批准号:
    9038428
  • 财政年份:
    2014
  • 资助金额:
    $ 42.38万
  • 项目类别:
Modeling chromosome 7 loss in Myelodysplasia-iPSCs
骨髓增生异常-iPSC 中 7 号染色体缺失的建模
  • 批准号:
    8788296
  • 财政年份:
    2014
  • 资助金额:
    $ 42.38万
  • 项目类别:
Genetic correction of human beta-thalassemic induced pluripotent stem cells
人β地中海贫血诱导多能干细胞的遗传校正
  • 批准号:
    8955926
  • 财政年份:
    2012
  • 资助金额:
    $ 42.38万
  • 项目类别:

相似海外基金

RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
  • 批准号:
    2327346
  • 财政年份:
    2024
  • 资助金额:
    $ 42.38万
  • 项目类别:
    Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
  • 批准号:
    2312555
  • 财政年份:
    2024
  • 资助金额:
    $ 42.38万
  • 项目类别:
    Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
  • 批准号:
    BB/Z514391/1
  • 财政年份:
    2024
  • 资助金额:
    $ 42.38万
  • 项目类别:
    Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
  • 批准号:
    ES/Z502595/1
  • 财政年份:
    2024
  • 资助金额:
    $ 42.38万
  • 项目类别:
    Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
  • 批准号:
    ES/Z000149/1
  • 财政年份:
    2024
  • 资助金额:
    $ 42.38万
  • 项目类别:
    Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
  • 批准号:
    23K24936
  • 财政年份:
    2024
  • 资助金额:
    $ 42.38万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
  • 批准号:
    2901648
  • 财政年份:
    2024
  • 资助金额:
    $ 42.38万
  • 项目类别:
    Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
  • 批准号:
    2301846
  • 财政年份:
    2023
  • 资助金额:
    $ 42.38万
  • 项目类别:
    Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
  • 批准号:
    488039
  • 财政年份:
    2023
  • 资助金额:
    $ 42.38万
  • 项目类别:
    Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
  • 批准号:
    23K16076
  • 财政年份:
    2023
  • 资助金额:
    $ 42.38万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了